Product Images Gabapentin

This text appears to show a chart or graph related to a pain study. It includes details about the mean pain score, different dosage periods, and the treatments being compared (Placebo vs. Gabapentin 3600 mg/day) over a certain period of weeks. The chart likely displays the pain scores at various time points during the study.*

This text provides information about a study involving pain management using different doses of Gabapentin. The study includes a baseline assessment and two different dosage periods - one lasting less than 3 weeks and another lasting 4 weeks with fixed doses. Placebo, 1800 mg/day Gabapentin, and 2400 mg/day Gabapentin are the three treatments being compared in terms of pain scores.*

This text provides data on the proportion of responders (patients with a 50% or greater reduction in pain score) in controlled studies on Postherpetic Neuralgia (PHN). The results are shown across different studies and treatment groups. Study 1 had 32% responders in the placebo (PBO) group and 34% in the GBP 3600 group. Study 2 had 12% responders in the PBO group, 14% in the GBP 1800 group, and no data is available for the GBP 2400 group. The data indicate the effectiveness of the treatments in managing PHN pain.*

This is a product label for Gabapentin capsules containing 300 mg of the active ingredient. It provides information on storage conditions, dosage instructions, manufacturer details, and a QR code for accessing the package insert for additional information. The capsules should be stored at temperatures between 20°C to 25°C, with excursions permitted to 15°C to 30°C. The label also warns of potential side effects like dizziness and advises keeping the medication out of reach of children. The medication is repackaged by Bryant Ranch Prepack, Inc. but manufactured by Aurobindo Pharma Limited.*